Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron
CEO, Mike Lampron
Source: Mach7 Technologies
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mach7 Technologies (M7T) receives purchase orders for its software and services totalling $3.6 million from US-based Trinity Health
  • The latest order supplements Trinity’s previous deal with M7T to purchase the company’s eUnity Enterprise Viewer in November 2020
  • M7T will provide Trinity a full diagnostic picture archiving and communication system (PACS) solution with a maximum value of $15.6 million over seven years
  • Shares are up 4.52 per cent to $1.04 each at 1:24 pm AEST

Mach7 Technologies (M7T) has received purchase orders for its software and services from Trinity Health totalling $3.6 million.

Based in Michigan, Trinity claims to be one of the largest multi-institutional Catholic healthcare delivery systems in the US, servicing communities at 92 hospitals and 100 continuing-care locations across 22 states.

In a statement today M7T said Trinity had placed orders for its Mach7 Enterprise Imaging Platform, eUnity Diagnostic Views, eUnity Enterprise Viewer and Mach7 Universal Worklist.

The company expects revenue from these orders to be recognised this financial year, with a further $3.8 million in support fees expected over the next seven years, taking the total contract value to $7.4 million.

The purchase follows the seven-year contract signed by the parties for the eUnity Enterprise Viewer, which was announced to the ASX in November last year.

In light of Trinity’s subsequent purchase of several other software and services from M7T, the company will now supply Trinity a full diagnostic picture archiving and communication system (PACS) solution.

According to Mach7, the total maximum value of the PACS solution is $15.6 million over seven years, including the original Enterprise Viewer contract.

The company’s CEO Mike Lampron said he was excited about the opportunity to [work] with Trinity Health.

“I believe the full Mach7 solution is well-positioned to deliver on the strategic objectives of Trinity’s Unified Clinical Imaging Platform Strategy and I look forward to being a part of their initiative,” he said.

Shares were up 4.52 per cent to $1.04 each at 1:24 pm AEST.

M7T by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…